TY - JOUR AU - Aaronson NK AU - Ahmedzai S AU - Bergman B AU - Bullinger M AU - Cull A AU - Duez NJ AU - Filiberti A AU - Fletchner H AU - Fleishman SB AU - de Haes JC TI - The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology JA - J Natl Cancer Inst PY - 1993/// VL - 85 SP - 365 EP - 376 PB - Cancer Research Campaign M3 - 10.1093/jnci/85.5.365 N1 - 10.1093/jnci/85.5.365 UR - http://dx.doi.org/10.1093/jnci/85.5.365 ER - TY - JOUR AU - Bleehen NM AU - Newlands ES AU - Lee SM AU - Thatcher N AU - Selby P AU - Calvert AH AU - Rustin GJS AU - Brampton M AU - Stevens MFG TI - Cancer research campaign phase II trial of temozolomide in metastatic melanoma JA - J Clin Oncol PY - 1995/// VL - 13 SP - 910 EP - 913 PB - Cancer Research Campaign ER - TY - JOUR AU - Bower M AU - Newlands ES AU - Bleehen NM AU - Brada M AU - Begent RJH AU - Calvert H AU - Colquhoun I AU - Lewis P AU - Brampton MH TI - Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma JA - Cancer Chemother Pharmacol PY - 1997/// VL - 40 SP - 484 EP - 488 PB - Cancer Research Campaign M3 - 10.1007/s002800050691 N1 - 10.1007/s002800050691 UR - http://dx.doi.org/10.1007/s002800050691 ER - TY - JOUR AU - Brada M AU - Thomas DGT AU - Bleehen NM AU - Roberts JT AU - Senanayake F AU - Abram P AU - Lantos PL AU - Moss TH AU - Ironside JW AU - Whaley JB AU - Stenning SP TI - JA - Proceedings of the American Society of Clinical Oncology PY - 1998/// VL - 17 SP - EP - PB - Cancer Research Campaign ER - TY - JOUR AU - Brock CS AU - Matthews JC AU - Brown G AU - Luthra SK AU - Brady F AU - Newlands ES AU - Price P TI - The kinetic behaviour of temozolomide in man JA - Proceedings of the American Society of Clinical Oncology PY - 1996/// VL - 15 SP - 475 EP - PB - Cancer Research Campaign ER - TY - JOUR AU - Brock CS AU - Matthews JC AU - Brown G AU - Newlands ES AU - Price P TI - In vivo demonstration of11C-temozolomide uptake by human recurrent high grade astrocytomas JA - Br J Cancer PY - 1997/// VL - 75 SP - 1241 EP - PB - Cancer Research Campaign ER - TY - JOUR AU - Burger PC AU - Vogel FS AU - Green SB AU - Strike TA TI - Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications JA - Cancer PY - 1985/// VL - 56 SP - 1106 EP - 1111 PB - Cancer Research Campaign M3 - 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2 N1 - 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2 UR - http://dx.doi.org/10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2 ER - TY - JOUR AU - Chamberlain MC AU - Kormanik PA TI - Practical guidelines for the treatment of malignant gliomas JA - West J Med PY - 1998/// VL - 168 SP - 114 EP - 120 PB - Cancer Research Campaign ER - TY - GEN AU - Fayers P AU - Aaronson N AU - Bjordal K AU - Sullivan M TI - JA - EORTC QLQ-C30 Scoring Manual PY - 1995/// VL - SP - EP - PB - Cancer Research Campaign ER - TY - JOUR AU - Fine HA AU - Dear KB AU - Loeffler JS AU - Black PM AU - Canellos GP TI - Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant glioma in adults JA - Cancer PY - 1993/// VL - 71 SP - 2585 EP - 2597 PB - Cancer Research Campaign M3 - 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S N1 - 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S UR - http://dx.doi.org/10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S ER - TY - JOUR AU - Feun LG AU - Savaraj N AU - Landy HJ TI - Drug resistance in brain tumors JA - J Neurooncol PY - 1994/// VL - 20 SP - 165 EP - 176 PB - Cancer Research Campaign ER - TY - JOUR AU - Forsyth PA AU - Cairncross JG TI - Chemotherapy for malignant gliomas JA - Baillieres Clin Neurol PY - 1996/// VL - 5 SP - 371 EP - 393 PB - Cancer Research Campaign ER - TY - JOUR AU - Jaeschke R AU - Singer J AU - Guyatt GH TI - Measurement of health status. Ascertaining the minimal clinically important difference JA - Control Clin Trials PY - 1989/// VL - 10 SP - 407 EP - 415 PB - Cancer Research Campaign M3 - 10.1016/0197-2456(89)90005-6 N1 - 10.1016/0197-2456(89)90005-6 UR - http://dx.doi.org/10.1016/0197-2456(89)90005-6 ER - TY - JOUR AU - Juniper EF AU - Guyatt GH AU - Willan A AU - Griffith LE TI - Determining a minimal important change in a disease-specific quality of life questionnaire JA - J Clin Epidemiol PY - 1994/// VL - 47 SP - 81 EP - 87 PB - Cancer Research Campaign M3 - 10.1016/0895-4356(94)90036-1 N1 - 10.1016/0895-4356(94)90036-1 UR - http://dx.doi.org/10.1016/0895-4356(94)90036-1 ER - TY - JOUR AU - King MT TI - The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30 JA - Qual Life Res PY - 1996/// VL - 5 SP - 555 EP - 567 PB - Cancer Research Campaign M3 - 10.1007/BF00439229 N1 - 10.1007/BF00439229 UR - http://dx.doi.org/10.1007/BF00439229 ER - TY - JOUR AU - Kumar ARV AU - Renaudin J AU - Wilson CB AU - Boldrey EB AU - Enot KJ AU - Levin VA TI - Procarbazine hydrochloride in the treatment of brain tumors JA - J Neurosurg PY - 1974/// VL - 40 SP - 365 EP - 371 PB - Cancer Research Campaign ER - TY - GEN AU - Levin VA AU - Leibel SA AU - Gutin PH TI - Neoplasms of the central nervous system JA - Cancer Principals and Practice of Oncology PY - 1997/// VL - SP - 2041 EP - 2042 PB - Cancer Research Campaign ER - TY - JOUR AU - McComb RD AU - Burger PC TI - Pathologic analysis of primary brain tumors JA - Neurol Clin PY - 1985/// VL - 3 SP - 711 EP - 728 PB - Cancer Research Campaign ER - TY - JOUR AU - Newlands ES AU - Blackledge GRP AU - Slack JA AU - Rustin GJS AU - Smith DB AU - Stuart NSA AU - Quarterman CP AU - Hoffman R AU - Stevens MFG AU - Brampton MH AU - Gibson AC TI - Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) JA - Br J Cancer PY - 1992/// VL - 65 SP - 287 EP - 291 PB - Cancer Research Campaign ER - TY - JOUR AU - Newlands ES AU - O/'Reilly SM AU - Glaser MG AU - Bower M AU - Evans H AU - Brock C AU - Brampton MH AU - Colquhoun I AU - Lewis P AU - Rice-Edwards JM AU - Illingworth RD AU - Richards PG TI - The Charing Cross Hospital experience with temozolomide in patients with gliomas JA - Eur J Cancer PY - 1996/// VL - 32A SP - 2236 EP - 2241 PB - Cancer Research Campaign ER - TY - JOUR AU - Newton HB AU - Junck L AU - Bromberg J AU - Page MA AU - Greenberg HS TI - Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure JA - Neurology PY - 1990/// VL - 40 SP - 1743 EP - 1746 PB - Cancer Research Campaign ER - TY - JOUR AU - O/'Reilly SM AU - Newlands ES AU - Glaser MG AU - Brampton M AU - Rice-Edwards JM AU - Illingworth RD AU - Richards PG AU - Kennard C AU - Colquhoun IR AU - Lewis P AU - Stevens MFG TI - Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours JA - Eur J Cancer PY - 1993/// VL - 29A SP - 940 EP - 942 PB - Cancer Research Campaign ER - TY - JOUR AU - Osoba D AU - Aaronson NK AU - Muller M AU - Sneeuw K AU - Hsu M-A AU - Yung WKA AU - Brada M AU - Newlands E TI - The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires JA - Qual Life Res PY - 1996/// VL - 5 SP - 139 EP - 150 PB - Cancer Research Campaign M3 - 10.1007/BF00435979 N1 - 10.1007/BF00435979 UR - http://dx.doi.org/10.1007/BF00435979 ER - TY - JOUR AU - Osoba D AU - Aaronson N AU - Zee B AU - Sprangers M AU - te Velde A TI - Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer JA - Qual Life Res PY - 1997/// VL - 6 SP - 103 EP - 108 PB - Cancer Research Campaign M3 - 10.1023/A:1026429831234 N1 - 10.1023/A:1026429831234 UR - http://dx.doi.org/10.1023/A:1026429831234 ER - TY - JOUR AU - Osoba D AU - Rodrigues G AU - Myles J AU - Zee B AU - Pater J TI - Interpreting the significance of changes in health-related quality-of-life scores JA - J Clin Oncol PY - 1998/// VL - 16 SP - 139 EP - 144 PB - Cancer Research Campaign ER - TY - JOUR AU - Patel M AU - McCully C AU - Godwin K AU - Balis F TI - Plasma and cerebrospinal fluid pharmacokinetics of temozolomide JA - Proceedings of the American Society of Clinical Oncology PY - 1995/// VL - 14 SP - 461 EP - PB - Cancer Research Campaign ER - TY - JOUR AU - Rodriguez LA AU - Prados M AU - Silver P AU - Levin VA TI - Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumours JA - Cancer PY - 1989/// VL - 64 SP - 2420 EP - 2423 PB - Cancer Research Campaign M3 - 10.1002/1097-0142(19891215)64:12<2420::AID-CNCR2820641204>3.0.CO;2-B N1 - 10.1002/1097-0142(19891215)64:12<2420::AID-CNCR2820641204>3.0.CO;2-B UR - http://dx.doi.org/10.1002/1097-0142(19891215)64:12<2420::AID-CNCR2820641204>3.0.CO;2-B ER - TY - JOUR AU - Stevens MFG AU - Hickman JA AU - Langdon SP AU - Chubb D AU - Vickers L AU - Stone R AU - Baig G AU - Goddard C AU - Gibson NW AU - Slack JA AU - Newton C AU - Lunt E AU - Fizames C AU - Lavelle F TI - Antitumor activity and pharmacokinetics in mice of 8-Carbamoyl-3-methylimidazo [5,1- d ]-1,2,3,5-tetrazin-4(3 H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine JA - Cancer Res PY - 1987/// VL - 47 SP - 5846 EP - 5852 PB - Cancer Research Campaign ER - TY - JOUR AU - Tsang LLH AU - Farmer PB AU - Gescher A AU - Slack JA TI - Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity JA - Cancer Chemother Pharmacol PY - 1990/// VL - 26 SP - 429 EP - 436 PB - Cancer Research Campaign ER - TY - GEN AU - Ware JEE Jr AU - Kosinski M AU - Keller SD TI - JA - SF-36 Physical and Mental Health Summary Scales: A User/'s Manual PY - /// VL - SP - EP - PB - Cancer Research Campaign ER -